Sinovac Biotech
CompanyChinaFounded 1999
Sinovac Biotech develops 2 assets, the furthest in phase 3 (FLU-v in influenza). Mostly vaccine acting on inflammation; based in China, founded in 1999.
- 2
- Assets
- Furthest stage
- Phase 3
- 5
- Trials
- 0
- Signals
Pipeline
2Inactivated influenza virus vaccine inducing protective antibody responses
Phase 3, Vaccine, Inflammation, influenza, influenza immunization
COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
Inactivated Omicron-strain SARS-CoV-2 stimulates protective immune responses against COVID-19.
Phase 2, Vaccine, COVID-19
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials5
- Similar companies6